Pfizer Global Medical Grants 2022 Growth Hormone Research RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Wednesday 6th, July 2022
External Deadline: Monday 11th, July 2022
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Geographic Scope: Global (excluding the United States)
Clinical Area: Short Stature/growth failure
Link to full RFP: 2022 Growth Hormone Research
Application Due Date: July 11, 2022
Specific Area of Interest: Research projects that will be considered for Pfizer support will advance the medical knowledge of short stature.
Projects submitted may include:
- – Morbidities in growth disorders
- – Strategies to evaluate and treat growth disorders including Quality of Life and Patient Reported Outcomes
- – Comparative pathophysiology of daily vs long-acting growth hormone
- – Evaluation of adherence of daily and long-acting growth hormone treatment
- – Novel strategies to address current unmet medical needs in short stature management which could be addressed with long-acting growth hormone treatment
- – Comparison of clinical effects of daily vs long-acting growth hormone
Projects may include translational or clinical research.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer (amanda.j.stein@pfizer.com).